Novo Nordisk has struck a collaboration and licensing deal with U.S. biotech Septerna to develop oral small molecule ...

Novo Nordisk A/S is partnering with US biotech Septerna Inc. on the development of oral pills for obesity and type-2 diabetes ...

Novo Nordisk is making yet another bet on obesity, offering Septerna more than $200 million in upfront and near-term payments ...

Novo Nordisk partners with U.S. biotech Septerna in a $2.2 billion deal to develop oral small molecule drugs for obesity and ...

Novo Nordisk is partnering with the biotech Septerna to develop oral obesity drugs, as it aims for more convenient weight ...

For the 2025 outlook, Novo Nordisk now expects 13-21% revenue increase at constant exchange rates (CER). Operating profit is expected at 16-24% growth. However, this forecast, 3% lower for revenue and ...

A pronouncement from President Trump about the category drove their share prices down, although not to bargain-basement ...

Mounjaro. Ozempic. Wegovy. Zepbound. All these are brand names linked in some way to diabetes and weight loss-or, as the ...

The best metric is not weight, but a particularly toxic kind of fat.

Tirzepatide conferred significantly greater weight loss than semaglutide at 72 weeks for adults with overweight or obesity, ...

People taking Eli Lilly's obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk's Wegovy in the first head-to-head study of the blockbuster medications. Clinical ...

Analysts are still crunching the numbers on the impact of President Donald Trump's executive order from Monday on drug pricing. HSBC analyst Rajesh Kumar says a 20% price cut in government channels ...